Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621001504808
Ethics application status
Approved
Date submitted
16/09/2021
Date registered
4/11/2021
Date last updated
10/12/2023
Date data sharing statement initially provided
4/11/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
Gut Bugs in Anorexia Nervosa
Scientific title
An open-label pilot trial of faecal microbiome transfer to restore the gut microbiome in anorexia nervosa
Secondary ID [1] 305167 0
None
Universal Trial Number (UTN)
U1111-1268-2837
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anorexia nervosa 323437 0
Condition category
Condition code
Mental Health 320990 320990 0 0
Eating disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Participants will receive 20 capsules containing the gut microbiota derived from four healthy, clinically-screened female stool donors. Each capsule contains 0.5 grams concentrated gut microbiota suspended in a cryoprotective solution (0.9% saline + 15% glycerol). Capsules will be swallowed with a glass of water under direct supervision from a research clinician or nurse. The dose will be split over two or four consecutive mornings depending on participant preference (i.e. 10 capsules/day or 5 capsules/day, all taken at the same time).
Intervention code [1] 321570 0
Treatment: Other
Comparator / control treatment
No control group.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 328769 0
Gut microbiome structure (assessed with faecal samples and using Bray Curtis Dissimilarity)
Timepoint [1] 328769 0
3-weeks pre-treatment, baseline (i.e. day before treatment), 3-weeks post-treatment
Secondary outcome [1] 400272 0
Gut microbiome composition and functional potential (composite outcome) assessed with faecal samples using bioBakery tools
Timepoint [1] 400272 0
3-weeks pre-treatment, baseline (i.e. day before treatment), 3-weeks, 6-weeks, 12-weeks post-treatment.
Secondary outcome [2] 400273 0
Adverse events associated with treatment
(assessed by study-specific questionnaire based on Common Terminology Criteria for
Adverse Events (CTCAE) manual v4.; specifically, participants will be asked to report on the following events: any changes in bowel movements, loose or bloody stools, abdominal pain, vomiting, nausea, fever, malodorous burps, fatigue, or any other symptom/s they have experienced.)
Timepoint [2] 400273 0
24 hours after each capsule dose, 1-week, 3-weeks, 6-weeks, 12-weeks post-treatment.
Secondary outcome [3] 400274 0
Tolerability 1: Proportion of participants who complete treatment. (based on study records)
Timepoint [3] 400274 0
Day 4 (after final capsule dose).
Secondary outcome [4] 400275 0
Eating disorder symptoms (assessed using the Eating Disorder Examination Questionnaire, version 6.0)
Timepoint [4] 400275 0
baseline, 6-weeks, 12-weeks post-treatment.
Secondary outcome [5] 400276 0
Nutritional blood markers (including sodium, potassium, creatinine, ferritin, total protein, albumin, alkaline phosphatase, alanine aminotransferase, aspartate transaminase, gamma-glutamyl transferase, folate, vitamin B12, cortisol, free thyroxine, thyroid stimulating hormone, and serotonin)
Timepoint [5] 400276 0
baseline, 6-weeks, 12-weeks post-treatment.
Secondary outcome [6] 400279 0
Faecal biomarkers of gut inflammation and permeability (composite outcome).
(test include: Calprotectin, Lactoferrin, M2-pyruvate kinase, and S100A12 assays)
Timepoint [6] 400279 0
baseline, 3-weeks, 6-weeks, 12-weeks post-treatment
Secondary outcome [7] 400280 0
BMI (provided by DXA scan)
Timepoint [7] 400280 0
baseline, 12-weeks post-treatment
Secondary outcome [8] 400281 0
Body composition (DXA scan)
Timepoint [8] 400281 0
baseline, 12-weeks post-treatment
Secondary outcome [9] 401942 0
Donor strain engraftment (assessed with faecal samples using strain profiling methods)
Timepoint [9] 401942 0
baseline, 3-weeks, 6-weeks, 12-weeks post-treatment
Secondary outcome [10] 401944 0
Tolerability 2: Proportion of participants who would consider having the treatment again if it was later proven to be beneficial in treating anorexia nervosa (assessed by Treatment Tolerability questionnaire).
Timepoint [10] 401944 0
Day 4 (after final capsule dose)
Secondary outcome [11] 401945 0
Depression symptoms (assessed using the Patient Health Questionnaire-9)
Timepoint [11] 401945 0
baseline, 6-weeks, 12-weeks post-treatment.
Secondary outcome [12] 401946 0
Anxiety symptoms (assessed using the Generalised Anxiety Disorder Assessment 7 questionnaire)
Timepoint [12] 401946 0
baseline, 6-weeks, 12-weeks post-treatment.

Eligibility
Key inclusion criteria
Participants:
- Biological female
- Age 16 – 32 years
- BMI 13 - 19 kg/m2
- formal diagnosis of anorexia nervosa by an eating disorder specialist (meets the DSM-5 criteria, 307.1)
- Medically stable
- Be able and willing to swallow treatment capsules and comply with the clinical assessments.

Donors:
- Female
- Age 18-32 years
- BMI 18.5 - 25.0 kg/m2
- Total body fat less than or equal to 33%
- Healthy diet (greater than or equal to 4 portions of fruit and vegetables per day)
- Regular exercise (moderate to vigorous physical activity for at least 3.5 hours per week)
- Regular bowel habit (at least once every two days)
Minimum age
16 Years
Maximum age
32 Years
Sex
Females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Participants:
- Known allergies to food and/or common medications
- Use of antibiotics or probiotics in the month prior to treatment
- Regular oral steroid treatment or daily application of potent topical steroids extensively to the body
- Compromised immune system
-Any chronic illness affecting gut or metabolic health
- Thoughts of self-harm and/or suicide ideation (assessed by PHQ-9)
- Current or planned pregnancy during the course of the study

Donors:
- Positive screening test for any transmissible pathogen or multi-drug resistant organism
- Gastrointestinal disease (e.g. inflammatory bowel disease, irritable bowel syndrome, coeliac disease, eosinophilic oesophagitis)
- Metabolic disorder (e.g. diabetes, metabolic syndrome, hypertension, dyslipidemia, dysglycemia)
- Impaired fasting glucose (>5.9 mmol/l) or elevated HbA1c (>41 mmol/mol)
- Asthma or eczema requiring regular prophylaxis or treatment
- Autism spectrum conditions
- Previous diagnosis of mental health issues including eating disorders
- Current or past history of malignancy
- Use of oral antibiotics or probiotics in the past 3 months
- Regular binge drinking (>5 standard alcoholic units/session at least once a week)
- Past or present use of recreational drugs, tobacco, or vaping
- Current or past pregnancy
- Overseas travel in the past 2 weeks
- UK residence in 1980-1996 for 6 months or longer

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Primary Outcome
The primary outcome was powered for a shift in gut microbiome structure from baseline that is above the natural drift of the gut microbiome over a 3-week period without intervention. To assess this we will need a minimum of 18 participants (80% power, alpha = 0.05). To account for a potential drop-out rate of 10%, we aim to recruit 20 participants.

Gut microbiome profiling will be performed on stool samples collected from participants 3-weeks before treatment, just before treatment (baseline), and 3-, 6-, and 12-weeks after treatment. Gut microbiome shifts will be assessed by calculating the Bray Curtis dissimilarity to baseline. To assess the primary outcome, a paired t-test will compare the shift in gut microbiome structure 3-weeks before treatment, to the shift in gut microbiome structure 3-weeks after treatment. No imputation will be performed for missing data.

Secondary Outcomes
Gut Microbiome
Changes in alpha-diversity and microbial gene richness will be assessed using paired t-tests (parametric) or Wilcoxon signed rank tests (non-parametric) as appropriate. Multivariate Association with Linear Models (MaAsLin2) will be used to identify any significant changes in microbiome features (e.g. microbial taxa, metabolic pathways) in response to treatment. The genetic similarity of donor and recipient strains (before and after treatment) will be compared to assess the proportion and stability of donor strain engraftment.

Demographics & Clinical Outcomes
Baseline demographics and clinical characteristics will be summarized using descriptive statistics. Changes in clinical and nutritional features from baseline will be assessed using paired t-tests (parametric) or Wilcoxon signed rank tests (non-parametric) as appropriate.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
22/08/2022
Actual
22/08/2022
Date of last participant enrolment
Anticipated
1/06/2023
Actual
6/11/2023
Date of last data collection
Anticipated
1/09/2023
Actual
27/11/2023
Sample size
Target
20
Accrual to date
Final
17
Recruitment outside Australia
Country [1] 24074 0
New Zealand
State/province [1] 24074 0
Auckland

Funding & Sponsors
Funding source category [1] 309555 0
Other
Name [1] 309555 0
The Rockfield Trust
Country [1] 309555 0
New Zealand
Primary sponsor type
University
Name
University of Auckland
Address
Liggins Institute
University of Auckland
85 Park Road
Grafton 1023
Auckland
New Zealand
Country
New Zealand
Secondary sponsor category [1] 310554 0
None
Name [1] 310554 0
Address [1] 310554 0
Country [1] 310554 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 309335 0
Central Health and Disability Ethics Committee
Ethics committee address [1] 309335 0
Ethics committee country [1] 309335 0
New Zealand
Date submitted for ethics approval [1] 309335 0
04/08/2021
Approval date [1] 309335 0
24/08/2021
Ethics approval number [1] 309335 0
21/CEN/212

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 113806 0
Prof Justin O'Sullivan
Address 113806 0
Liggins Institute
University of Auckland
85 Park Road
Grafton
Auckland 1023
New Zealand
Country 113806 0
New Zealand
Phone 113806 0
+64 9 923 9868
Fax 113806 0
Email 113806 0
[email protected]
Contact person for public queries
Name 113807 0
Brooke Wilson
Address 113807 0
Liggins Institute
University of Auckland
85 Park Road
Grafton
Auckland 1023
New Zealand
Country 113807 0
New Zealand
Phone 113807 0
+64 9 923 6691
Fax 113807 0
Email 113807 0
[email protected]
Contact person for scientific queries
Name 113808 0
Brooke Wilson
Address 113808 0
Liggins Institute
University of Auckland
85 Park Road
Grafton
Auckland 1023
New Zealand
Country 113808 0
New Zealand
Phone 113808 0
+64 9 923 6691
Fax 113808 0
Email 113808 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
1. de-identified post-filtered metagenomic sequencing data will be shared on NCBI's sequence read archive (SRA)

2. de-identified clinical data may be made available for future research upon valid requests to the Liggins Institute Clinical Data Research Hub Data Access Committee.
When will data be available (start and end dates)?
Upon publication of the study findings with no end date.
Available to whom?
Metagenomic sequencing data will be accessible to the public via NCBI's SRA.

Clinical data will only be made available to researchers who meet the the data access requirements set out by the Liggins Institute's data access committee.
Available for what types of analyses?
Gut microbiome characterisation
FMT meta-analyses
How or where can data be obtained?
metagenomic sequencing data will be shared on NCBI's Sequence Read Archive (SRA)

clinical data access requests to be sent to the Liggins Institute's Clinical Data Research Hub Data Access Committee (email: [email protected])


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
13233Study protocol  [email protected] Planning to publish the trial protocol in a scient... [More Details]



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseAn open-label pilot trial of faecal microbiome transfer to restore the gut microbiome in anorexia nervosa: protocol.2023https://dx.doi.org/10.1136/bmjopen-2022-070616
N.B. These documents automatically identified may not have been verified by the study sponsor.